Burgdorf and Eindhoven (NL), 04.10.2018, 7.00 a.m. – Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, and Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration to jointly develop and deploy new digital self-medication adherence monitoring services based on Ypsomed’s connected devices and Philips’ cloud-based HealthSuite Digital Platform. The two companies agree to build a solution for Ypsomed’s new SmartServices™ based on Philips HealthSuite Digital Platform. The combination of Ypsomed connected self-medication devices with Philips’ HealthSuite Digital Platform will allow Ypsomed’s pharmaceutical customers to deliver value-added services for enhanced patient outcomes.

Ypsomed expands to more countries with its YpsoPump insulin pump

Press Releases Ypsomed Group

Burgdorf – Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.